Allakos Inc

NASDAQ ALLK

Data sourced from

and

Download Data

Allakos Inc Short-Term Investments 2 year CAGR for the quarter ending March 31, 2024: -32.39%

Allakos Inc Short-Term Investments 2 year CAGR is -32.39% for the quarter ending March 31, 2024, a 19.71% change year over year. Short-Term Investments are investments that are expected to be converted into cash within a year. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Allakos Inc Short-Term Investments for the quarter ending March 31, 2023 was USD 158.75 M, a -24.55% change year over year.
Allakos Inc Short-Term Investments for the quarter ending March 31, 2022 was USD 210.41 M, a -52.82% change year over year.
Allakos Inc Short-Term Investments for the quarter ending March 31, 2021 was USD 445.94 M, a 29.69% change year over year.
Allakos Inc Short-Term Investments for the quarter ending March 31, 2020 was USD 343.86 M, a 153.35% change year over year.

NASDAQ: ALLK

Allakos Inc

CEO	Dr. Robert Alexander Ph.D.
IPO Date	July 19, 2018
Location	United States
Headquarters	975 Island Drive, Redwood City, CA, United States, 94065
Employees	131
Sector	Healthcare
Industry	Biotechnology

Description

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Key trends